Clinical Trials Logo

HER2-positive Breast Cancer clinical trials

View clinical trials related to HER2-positive Breast Cancer.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 4

NCT ID: NCT03881878 Not yet recruiting - Clinical trials for HER2-positive Breast Cancer

TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery

Start date: May 27, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study was phase IB-II clinical trial that designed to evaluate the efficacy and safety of docetaxel + atezolizumab + Herceptin sc plus pertuzumab(TAHP) plus adjuvant therapy of atezolizumab + trastuzumab + pertuzumab(AHP) after surgery in female patients with HER2-positive early breast cancer. Adjuvant AHP (atezolizumab + Herceptin SC + pertuzumab) will be continued for remaining 1 year. For non-p CR patients, they are going to treat with 4 cycles of AC rather than Taxane only before AHP adjuvant therapy.

NCT ID: NCT03847818 Not yet recruiting - Clinical trials for HER2-positive Breast Cancer

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

This is a prospective, open-label,multicenter Phase II study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus chemotherapy as neoadjuvant treatment in HER2 positive early stage or locally advanced breast cancer.

NCT ID: NCT03684863 Not yet recruiting - Clinical trials for HER2-positive Breast Cancer

Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Start date: October 2018
Phase: Phase 2
Study type: Interventional

This study is designed to investigate the efficacy and safety of capecitabine, as a postoperative adjuvant chemotherapy, for HER-2 positive breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.